A potential role for crystallization inhibitors in treatment of Alzheimer's disease

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 118-119

  Grases, Fèlix ^a,b   Costa Bauzà, Antònia ^a,b   Prieto, Rafael M ^a,b  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM SALT; HYDROXYAPATITE; INSULIN; MELATONIN; PHYTATE; PYROPHOSPHATE; SEROTONIN;

AGE; ALZHEIMER DISEASE; ARTICLE; CALCIFICATION; CRYSTALLIZATION; DEMENTIA; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; IMMUNE SYSTEM; INSULIN RESISTANCE; METABOLIC DISORDER; PATHOGENESIS; PINEAL BODY; PRIORITY JOURNAL; RISK FACTOR; TISSUE INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; CALCIUM; DIPHOSPHATES; DURAPATITE; HUMANS; MELATONIN; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEUROPROTECTIVE AGENTS; PINEAL GLAND; RISK FACTORS; SALTS;

EID: 70549110117     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.07.029     Document Type: Article

References (28)

1. Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12 (1991) 383-388
2. Mudher A., and Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci 25 (2002) 22-26
3. Nistor M., Don M., Parekh M., Sarsoza F., Goodus M., Lopez G.E., et al. Alpha- and beta-secretase activity as a function of age and beta-amyloid in down syndrome and normal brain. Neurobiol Aging 28 (2007) 1493-1506
4. Lott I.T., and Head E. Alzheimer disease and down syndrome: factors in pathogenesis. Neurobiol Aging 26 (2005) 383-389
5. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., et al. Dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333 (1995) 1242-1247
6. Biessels G.J., and Kappelle L.J. Utrecht diabetic encephalopathy study group. increased risk of Alzheimer's disease in Type II Diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem Soc Trans 33 (2005) 1041-1044
7. Roriz-Filho S.J., Sá-Roriz T.M., Rosset I., Camozzato A.L., Santos A.C., Chaves M.L., et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792 (2009) 432-443
8. Allegra M., Reiter R.J., Tan D.X., Gentile C., Tesoriere L., and Livrea M.A. The chemistry of melatonin's interaction with reactive species. J Pineal Res 34 (2003) 1-10
9. Pappolla M.A., Chyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J., et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 107 (2000) 203-231
10. Reiter R.J. Antioxidant actions of melatonin. Adv Pharmacol 38 (1997) 103-117
11. Sharman E.H., and Bondy S.C. Effects of age and dietary antioxidants on cerebral electron transport chain activity. Neurobiol Aging 22 (2001) 629-634
12. De Butte M., Fortin T., and Pappas B.A. Pinealectomy: behavioral and neuropathological consequences in a chronic cerebral hypoperfusion model. Neurobiol Aging 23 (2002) 309-317
13. De Butte M., and Pappas B.A. Pinealectomy causes hippocampal CA1 and CA3 cell loss: reversal by melatonin supplementation. Neurobiol Aging 28 (2007) 306-313
14. Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 20 (2005) 291-303
15. Cardinali D.P., Furio A.M., and Reyes M.P. Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. Ann NY Acad Sci 1057 (2005) 327-336
16. Mahlberg R., Tilman A., Salewski L., and Kunz D. Normative data on the daily profile of urinary 6-sulfatoxymelatonin in healthy subjects between the ages of 20 and 84. Psychoneuroendocrinology 31 (2006) 634-641
17. Zhou J.N., Liu R.Y., Van Heerikhuize J., Hofman M.A., and Swaab D.F. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 34 (2003) 11-16
18. Liu R.Y., Zhou J.N., Van Heerikhuize J., Hofman M.A., and Swaab D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 84 (1999) 323-327
19. Skene D.J., and Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 38 (2003) 199-206
20. Jouvet A., Fevre-Montange M., Besancon R., Derrington E., Saint-Pierre G., Belin M.F., et al. Structural and ultrastructural characteristics of human pineal gland, and pineal parenchymal tumors. Acta Neuropathol (Berl) 88 (1994) 334-348
21. Zimmermann R.A., and Bilaniuk L.T. Age-related incidence of pineal calcification detected by computed tomography. Radiology 142 (1981) 659-662
22. Tomazic B.B. Physiochemical principles of cardiovascular calcification. Z Kardiol 90 (2001) 68-80
23. Grases F., Simonet B.M., Prieto R.M., and March J.G. Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 86 (2001) 225-231
24. Grases F., Simonet B.M., Prieto R.M., and March J.G. Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 12 (2001) 595-601
25. Mahlberg R., Walther S., Kalus P., Bohner G., Haedel S., Reischies F., et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging 29 (2008) 203-209
26. Pappolla M.A., Simovich M.J., Bryant-Thomas T., Chyan Y.J., Poeggeler B., Dubocovich M., et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res 32 (2002) 135-142
27. Wolden-Hanson T., Mitton D.R., McCants R.L., Yellon S.M., Wilkinson C.W., Matsumoto A.M., et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141 (2000) 487-497
28. Cagnacci A., Arangino S., Renzi A., Paoletti A.M., Melis G.B., Cagnacci P., et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf) 54 (2001) 339-346